BACKGROUND: We sought to identify the significant prognostic parameters of patients with osteosarcoma over the past three decades using a population-based registry. METHODS: A total of 3765 patients with osteosarcoma were identified in the SEER database. Information regarding patient demographics, clinical and treatment characteristics, cause of death and survival were extracted. Kaplan-Meier, Log-Rank, and Cox regression were used for analysis. RESULTS: On multivariate analysis only age group '<25 years', 'local' stage and 'low' grade, 'appendicular skeleton' and employment of 'surgical resection' showed a disease-specific survival benefit with a P value < 0.001. The long-term survival improved in the interval from 1973 to 1985 from approximately 55 to 65% but subsequent improvement has been limited only to patients with high-grade disease. CONCLUSION: When comparing survival rates by decade of diagnosis, it appears that improvement in survival since 1985 is limited to patients with high-grade disease only. LEVEL OF EVIDENCE: The level of evidence for this article is 2.
BACKGROUND: We sought to identify the significant prognostic parameters of patients with osteosarcoma over the past three decades using a population-based registry. METHODS: A total of 3765 patients with osteosarcoma were identified in the SEER database. Information regarding patient demographics, clinical and treatment characteristics, cause of death and survival were extracted. Kaplan-Meier, Log-Rank, and Cox regression were used for analysis. RESULTS: On multivariate analysis only age group '<25 years', 'local' stage and 'low' grade, 'appendicular skeleton' and employment of 'surgical resection' showed a disease-specific survival benefit with a P value < 0.001. The long-term survival improved in the interval from 1973 to 1985 from approximately 55 to 65% but subsequent improvement has been limited only to patients with high-grade disease. CONCLUSION: When comparing survival rates by decade of diagnosis, it appears that improvement in survival since 1985 is limited to patients with high-grade disease only. LEVEL OF EVIDENCE: The level of evidence for this article is 2.
Authors: Paul A Meyers; Cindy L Schwartz; Mark D Krailo; John H Healey; Mark L Bernstein; Donna Betcher; William S Ferguson; Mark C Gebhardt; Allen M Goorin; Michael Harris; Eugenie Kleinerman; Michael P Link; Helen Nadel; Michael Nieder; Gene P Siegal; Michael A Weiner; Robert J Wells; Richard B Womer; Holcombe E Grier Journal: J Clin Oncol Date: 2008-02-01 Impact factor: 44.544
Authors: G Bacci; P Picci; S Ferrari; M Orlandi; P Ruggieri; R Casadei; A Ferraro; R Biagini; A Battistini Journal: Cancer Date: 1993-02-15 Impact factor: 6.860
Authors: Phyllis A Wingo; Patricia M Jamison; Robert A Hiatt; Hannah K Weir; Paul M Gargiullo; Mary Hutton; Nancy C Lee; H Irene Hall Journal: Cancer Causes Control Date: 2003-03 Impact factor: 2.506
Authors: Craig C Earle; Ann B Nattinger; Arnold L Potosky; Kathleen Lang; Rajiv Mallick; Mark Berger; Joan L Warren Journal: Med Care Date: 2002-08 Impact factor: 2.983
Authors: Juan C Gutierrez; Anne C Fischer; Juan E Sola; Eduardo A Perez; Leonidas G Koniaris Journal: Pediatr Surg Int Date: 2007-05-03 Impact factor: 2.003
Authors: Xin Hua Long; Yun Fei Zhou; Ai Fen Peng; Zhi Hong Zhang; Xuan Yin Chen; Wen Zhao Chen; Jia Ming Liu; Shan Hu Huang; Zhi Li Liu Journal: Tumour Biol Date: 2015-01-08
Authors: Andrew C Pedtke; Rosanna L Wustrack; Andrew S Fang; Robert J Grimer; Richard J O'Donnell Journal: Clin Orthop Relat Res Date: 2012-03 Impact factor: 4.176
Authors: Xuan Yin Chen; Hui Bing Ruan; Xin Hua Long; Ai Fen Peng; Long Dian Zhou; Jia Ming Liu; Yang Zhou; Zhi Li Liu Journal: Exp Ther Med Date: 2017-03-29 Impact factor: 2.447
Authors: Jianning Tao; Ming-Ming Jiang; Lichun Jiang; Jason S Salvo; Huan-Chang Zeng; Brian Dawson; Terry K Bertin; Pulivarthi H Rao; Rui Chen; Lawrence A Donehower; Francis Gannon; Brendan H Lee Journal: Cancer Cell Date: 2014-09-08 Impact factor: 31.743